Semaglutide can help the body make more insulin and improves insulin sensitivity, which in turn lowers blood-glucose levels ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Novo Nordisk (NYSE: NVO) and Intuitive Surgical (NASDAQ: ISRG) are both healthcare leaders, but they operate in different ...

Altimmune, Inc. remains a high-risk, high-reward play as it approaches a pivotal 48-week MASH data readout for pemvidutide. ALT's pemvidutide shows strong MASH resolution and weight loss, but has not ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

Policy swings have made it a slippery year for pharma ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients. Semaglutide is Novo Nordisk's largest growth driver, and it has not performed ...

Fosun is joining the fray through its subsidiary Yao Pharma, which has granted Pfizer an exclusive worldwide license to ...